Adalimumab in Crohn's disease.
Although the advent of infliximab has changed the treatment paradigm and goals in inflammatory bowel diseases (IBD), it does not provide a cure for IBD and recent evidence has demonstrated that the immunogenicity of this chimeric anti-TNF antibody is associated with secondary loss of response and intolerance. In ulcerative colitis (UC) the efficacy of infliximab was demonstrated in two large clinical trials, but long-term maintenance efficacy data are lacking. Novel biological agents have entered clinical development and pioneering trials have been reported in the last two years. For Crohn's disease (CD) two anti-TNF agents, the fully human IgG1 anti-TNF monoclonal adalimumab and the humanized pegylated Fab-fragment certolizumab-pegol and the humanized anti alpha4 integrin IgG4 antibody both have demonstrated efficacy as maintenance agents. Adalimumab has been approved to treat active rheumatoid arthritis, psoriatric arthritis, and ankylosing spondylitis, and recently moderate-to-severe luminal CD has been added as an indication for this agent both by the FDA and EMEA. Further evidence is needed to establish the therapeutic potential of adalimumab in fistulizing CD and in UC. The benefit to risk ratio of anti-TNF agents in refractory IBD is clearly positive and since most of the toxicity is class specific, adalimumab is expected to have a safety profile similar to that of infliximab except for adverse events related to infusions.
Van Assche
Gert
G
Division of Gastroenterology, University of Leuven, Leuven, Belgium.
Vermeire
Séverine
S
Rutgeerts
Paul
P
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Clin Gastroenterol Hepatol. 2006 Jul;4(7):888-93
16797249
Clin Gastroenterol Hepatol. 2004 Jul;2(7):542-53
15224278
JAMA. 2006 May 17;295(19):2275-85
16705109
Inflamm Bowel Dis. 2004 Jul;10(4):333-8
15475739
Ann Rheum Dis. 2007 Jul;66(7):921-6
17301106
N Engl J Med. 2002 Aug 8;347(6):417-29
12167685
Gut. 1994 Mar;35(3):360-2
8150347
Inflamm Bowel Dis. 2007 Nov;13(11):1323-32
17636564
Arthritis Rheum. 2007 May;56(5):1433-9
17469100
World J Gastroenterol. 2007 Apr 28;13(16):2328-32
17511032
Clin Gastroenterol Hepatol. 2006 May;4(5):621-30
16678077
N Engl J Med. 1999 May 6;340(18):1398-405
10228190
N Engl J Med. 2007 Jul 19;357(3):239-50
17634459
Methods. 2005 May;36(1):3-10
15848070
N Engl J Med. 2007 Jul 19;357(3):228-38
17634458
Gastroenterology. 2007 Jan;132(1):52-65
17241859
Am J Gastroenterol. 2004 Oct;99(10):1984-9
15447761
Aliment Pharmacol Ther. 2007 Feb 15;25(4):409-18
17269996
Gut. 2005 May;54(5):617-22
15831904
Gut. 2002 Feb;50(2):206-11
11788561
N Engl J Med. 2003 Feb 13;348(7):601-8
12584368
Gastroenterology. 2001 Nov;121(5):1145-57
11677207
Arthritis Rheum. 2005 Nov;52(11):3403-12
16255017
Gastroenterology. 2002 Jan;122(1):7-14
11781274
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22
15852250
Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
16472588
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S194-8
15983899
Gastroenterology. 2006 Mar;130(3):650-6
16530505
Lancet. 2002 May 4;359(9317):1541-9
12047962
Ann Intern Med. 2007 Jun 19;146(12):829-38
17470824
Gastroenterology. 2003 Jul;125(1):32-9
12851868
N Engl J Med. 1997 Oct 9;337(15):1029-35
9321530
Ann Rheum Dis. 2006 Jul;65(7):889-94
16439435
Gastroenterology. 2005 Sep;129(3):807-18
16143120
N Engl J Med. 2001 Oct 11;345(15):1098-104
11596589
Inflamm Bowel Dis. 2006 Jan;12(1):22-8
16374254
Aliment Pharmacol Ther. 2001 Apr;15(4):463-73
11284774
Aliment Pharmacol Ther. 2005 Feb 1;21(3):251-8
15691299
Gastroenterology. 2003 Apr;124(4):917-24
12671888
Gut. 2007 Sep;56(9):1232-9
17299059
N Engl J Med. 2004 Feb 26;350(9):876-85
14985485
Gastroenterology. 2001 Nov;121(5):1088-94
11677200
Methods. 2005 May;36(1):61-8
15848075
Gastroenterology. 2004 Feb;126(2):402-13
14762776
Gut. 2004 Jan;53(1):70-7
14684579
Gastroenterology. 2003 Jun;124(7):1774-85
12806611